This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In the September issue of Pharmaceutical Executive, Lev Gerlovin addresses four main questions that US drugmakers must answer to cope with the evolving payer landscape given rising drug prices. To read the article, click the link below.
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
